PET/CT imaging of clear cell renal cell carcinoma with 124I labeled chimeric antibody | Zendy

Eamonn Bahnson | Zendy; Douglas A. Murrey | Zendy; Cathy M. Mojzisik | Zendy; Nathan C. Hall | Zendy; Humberto J. MartinezSuarez | Zendy; Michael V. Knopp | Zendy; Edward W. Martin | Zendy; Stephen P. Povoski | Zendy; Robert R. Bahnson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

PET/CT imaging of clear cell renal cell carcinoma with 124I labeled chimeric antibody

Author(s) -

Eamonn Bahnson,

Douglas A. Murrey,

Cathy M. Mojzisik,

Nathan C. Hall,

Humberto J. MartinezSuarez,

Michael V. Knopp,

Edward W. Martin,

Stephen P. Povoski,

Robert R. Bahnson

Publication year - 2009

Publication title -

therapeutic advances in urology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.115

H-Index - 30

eISSN - 1756-2880

pISSN - 1756-2872

DOI - 10.1177/1756287209105264

Subject(s) - medicine , renal cell carcinoma , antibody , cancer research , pathology , nuclear medicine , immunology

Clear cell renal cell carcinoma (ccRCC) presents problems for urologists in diagnosis, treatment selection, intraoperative surgical margin analysis, and long term monitoring. In this paper we describe the development of a radiolabeled antibody specific to ccRCC (124I-cG250) and its potential to help urologists manage each of these problems. We believe 124I-cG250, in conjunction with perioperative Positron emission tomography/ computed tomography imaging and intraoperative handheld gamma probe use, has the potential to diagnose ccRCC, aid in determining a proper course of treatment (operative or otherwise), confirm complete resection of malignant tissue in real time, and monitor patients post-operatively.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research